Whitepaper: SARS-CoV-2 Omicron spike protein and antibodies available
Sino Biological has developed recombinant Omicron Spike RBD protein and antibody reacting with Omicron to support the study of Omicron variant.
List view / Grid view
Sino Biological has developed recombinant Omicron Spike RBD protein and antibody reacting with Omicron to support the study of Omicron variant.
Read about our comprehensive portfolio of rigorously developed kits harnessing the ultrasensitive Single Molecule Counting (SMC™) technology.
Dr Pushpanathan Muthuirulan explores why messenger RNA (mRNA) is advantageous for vaccine development and how the COVID-19 pandemic has accelerated its progress within the pharmaceutical industry.
Infusions of purified IL-27 regulatory B cells (I27-Bregs) reduced symptoms in mouse models of multiple sclerosis and autoimmune uveitis.
Scientists have found that SARS-CoV-2 can knock out an important molecular pathway linked to an immune complex called MHC class I.
The new nanoparticle adjuvant improved antibody production following vaccination against HIV, diphtheria and influenza in mouse models.
Scientists used a new screen to identify FAM72A as a cause of mutagenesis that affects antibody development in COVID-19 and cancer.
Everest Medicines and Providence Therapeutics have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant.
A new study links tumour necrosis factor seen in rheumatoid arthritis with T cell dysfunction, potentially leading to new therapies.
The study is the first in-depth look at links between COVID-19 severity and gene expression in immune cells and may guide future therapies.
Removing stress hormones in mouse models restored proper function to immune cells and epithelial cells, pointing to new Crohn's treatments.
Scientists used a CRISPR-based screen to find that inhibiting MTHFD2 reduces disease severity in inflammatory disease models.
Scientists targeted a mouse's own cells using a synthetic molecule called EEZE, presenting a novel way to treat pneumonia.
A new study claims that future COVID-19 vaccines should activate T cells to attack infected cells expressing replication proteins.
Neutralising monoclonal antibodies protected aged macaque monkeys from SARS-CoV-2 and reduced inflammation, including in cerebrospinal fluid, a new study has shown.